iCardiac Selected by Top 10 Pharmaceutic...( Executes Mas...)

Executes Master Services Agreement Covering Highly Automated QT(sm) and Dynamic QTbtb(sm) Solutions

Rochester, New York (PRWEB) July 2, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has executed a master services agreement with a top 10 pharmaceutical company covering both iCardiac's Highly Automated QT as well as Dynamic QTbtb solutions for Phase I and Thorough QT (TQT) studies.

"We are enthusiastic about our continued progress in delivering the next generation of advanced methods for evaluating pharmaceutical cardiac safety," said Sasha Latypova, Executive Vice President. "Our technology and service solution is meeting a critical need for pharmaceutical developers to both increase precision of early clinical cardiac safety studies as well as minimize the current unacceptably high rate of false-positive QTc findings which can lead to unnecessary termination of promising new medicines in development."

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS te
'/>"/>